{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:29Z","timestamp":1788412469084,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obesity is a major global health issue. While tirzepatide demonstrates robust weight reduction in clinical trials, data comparing low maintenance doses (2.5 vs. 5\u2009mg) in non\u2010diabetic adults with obesity remain limited. This study evaluated the comparative efficacy and safety of 2.5 versus 5\u2009mg tirzepatide combined with lifestyle intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicentre, prospective, non\u2010randomised cohort study enrolled non\u2010diabetic Japanese adults (18\u201365\u2009years) with BMI \u2265\u200930\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or \u2265\u200927\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with comorbidities. Patients initiated tirzepatide at 2.5\u2009mg weekly; after 4\u2009weeks, the dose was maintained at 2.5\u2009mg or increased to 5\u2009mg based on shared decision\u2010making. All participants received standardised dietary and exercise counselling. The primary outcome was the proportion achieving BMI &lt;\u200925\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or &gt;\u200915% body weight reduction at 6\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 112 participants analysed (58 on 2.5\u2009mg, 54 on 5\u2009mg), baseline characteristics were well balanced (mean BMI 30.8\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). At 6\u2009months, the primary outcome was achieved in 62.1% of the 2.5\u2009mg group and 63.0% of the 5\u2009mg group (HR 0.93, 95% CI 0.58\u20131.49;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.772). Mean percent weight loss was \u221215.3% and \u221216.1%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.563), with similar reductions in BMI, skeletal muscle mass, and bone mass. Adherence to dietary therapy was excellent in both groups (96.4%), while exercise adherence was 37.5%. Adverse events were more frequent with 5\u2009mg (50% vs. 35%), primarily gastrointestinal symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In non\u2010diabetic Japanese adults with obesity, 2.5 and 5\u2009mg tirzepatide combined with lifestyle modification yielded similar weight loss at 6\u2009months, with better tolerability at the lower dose. These findings support the potential utility of low\u2010dose tirzepatide strategies in real\u2010world practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71162","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:59:19Z","timestamp":1785290359000},"page":"9395-9402","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low\u2010Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5\u2009mg Versus 5\u2009mg in Non\u2010Diabetic Japanese Adults"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-2709","authenticated-orcid":false,"given":"Michitaka","family":"Amioka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine Hiroshima Cardiovascular Clinic  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyo","family":"Amioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Hiroshima Cardiovascular Clinic  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Onomichi General Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sairaku","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16330"},{"key":"e_1_2_9_5_1","volume-title":"Guidelines for the Management of Obesity Disease 2022","author":"Japan Society for the Study of Obesity","year":"2022"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0b013e318213fefb"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1491931"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16330"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01540-7"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00377-2"},{"issue":"1","key":"e_1_2_9_13_1","first-page":"39","article-title":"Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT\u2010CN Randomized Clinical Trial","volume":"332","author":"Zhao L.","year":"2024","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16554"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16275"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:21:47Z","timestamp":1788409307000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/dom.71162"],"URL":"https:\/\/doi.org\/10.1111\/dom.71162","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.71162\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71162\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2026-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}